Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach

Rajagopal et al., Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Curcumin for COVID-19
15th treatment shown to reduce risk in February 2021, now with p = 0.0000000096 from 27 studies.
No treatment is 100% effective. Protocols combine treatments.
5,300+ studies for 116 treatments. c19early.org
In Silico study of several phytochemical compounds from Curcuma longa (turmeric) and Andrographis paniculata for their potential activity against COVID-19 by targeting the SARS-CoV-2 main protease. Molecular docking analysis found the turmeric compounds cyclocurcumin and curcumin and the Andrographis paniculata compounds andrographolide and dihydroxy dimethoxy flavone bind significantly stronger to the SARS-CoV-2 protease compared to hydroxychloroquine, with favorable ADMET properties. The ligands exhibited similar binding modes, with key interactions mediated by several conserved residues in the protease active site. MM-GBSA binding energy calculations further confirmed the stability of the ligand-protease complexes. Overall, the turmeric and Andrographis paniculata compounds show promising in silico activity against the SARS-CoV-2 protease, warranting further in vitro and in vivo evaluation of their potential benefits for COVID-19 treatment.
51 preclinical studies support the efficacy of curcumin for COVID-19:
In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spikeA,1,2,7,12,14,20,23 (and specifically the receptor binding domainB,10,13,16), MproC,1,2,7,9,11-13,15,16,18,21,23,24,26,40, RNA-dependent RNA polymeraseD,1,2,13,22, PLproE,2, ACE2F,14,15,17, nucleocapsidG,8,25, nsp10H,25, and helicaseI,29 proteins. In Vitro studies demonstrate inhibition of the spikeA,34 (and specifically the receptor binding domainB,43), MproC,19,34,40,42, ACE2F,43, and TMPRSS2J,43 proteins, and inhibition of spike-ACE2 interactionK,27. In Vitro studies demonstrate efficacy in Calu-3L,41, A549M,34, 293TN,3, HEK293-hACE2O,19,32, 293T/hACE2/TMPRSS2P,33, Vero E6Q,9,13,23,32,34,36,37,39,41, and SH-SY5YR,31 cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants10, decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells39, alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress3, may limit COVID-19 induced cardiac damage by inhibiting the NF-κB signaling pathway which mediates the profibrotic effects of the SARS-CoV-2 spike protein on cardiac fibroblasts28, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity35.
Study covers curcumin and andrographolide.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The receptor binding domain is a specific region of the spike protein that binds ACE2 and is a major target of neutralizing antibodies. Focusing on the precise binding site allows highly specific disruption of viral attachment with reduced potential for off-target effects.
c. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
d. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
e. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
f. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
g. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
h. Non-structural protein 10 (nsp10) serves as an RNA chaperone and stabilizes conformations of nsp12 and nsp14 in the replicase-transcriptase complex, which synthesizes new viral RNAs. Nsp10 disruption may destabilize replicase-transcriptase complex activity.
i. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
j. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
k. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
l. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
m. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
n. 293T is a human embryonic kidney cell line that can be engineered for high ACE2 expression and SARS-CoV-2 susceptibility. 293T cells are easily transfected and support high protein expression.
o. HEK293-hACE2 is a human embryonic kidney cell line with high ACE2 expression and SARS-CoV-2 susceptibility. Cells have been transfected with a plasmid to express the human ACE2 (hACE2) protein.
p. 293T/hACE2/TMPRSS2 is a human embryonic kidney cell line engineered for high ACE2 and TMPRSS2 expression, which mimics key aspects of human infection. 293T/hACE2/TMPRSS2 cells are very susceptible to SARS-CoV-2 infection.
q. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
r. SH-SY5Y is a human neuroblastoma cell line that exhibits neuronal phenotypes. It is commonly used as an in vitro model for studying neurotoxicity, neurodegenerative diseases, and neuronal differentiation.
Rajagopal et al., 16 Oct 2020, peer-reviewed, 4 authors. Contact: rkalirajan@ymail.com (corresponding author), rkalirajan@jssuni.edu.in.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperCurcuminAll
Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach
Kalirajan Rajagopal, Potlapati Varakumar, Aparma Baliwada, Gowramma Byran
Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x
Background: In early 2020, many scientists are rushing to discover novel drugs and vaccines against the coronavirus, and treatments for COVID-19, because coronavirus disease 2019 (COVID-19), a life-threatening viral disease, affected first in China and quickly spread throughout the world. In this article, in silico studies have been performed to explore the binding modes of chemical constituents for natural remedies like Curcuma longa (turmeric) and Andrographis paniculata against COVID-19 (PDB ID 5R82) targeting coronavirus using Schrodinger suit 2019-4. The molecular docking studies are performed by the Glide module, in silico ADMET screening was performed by the QikProp module, and binding energy of ligands was calculated using the Prime MM-GB/SA module. Results: The chemical constituents from turmeric like cyclocurcumin and curcumin and from Andrographis paniculata like andrographolide and dihydroxy dimethoxy flavone are significantly binding with the active site of SARS CoV-2 main protease with Glide score more than -6 when compared to the currently used drugs hydroxychloroquine (-5.47) and nelfinavir (-5.93). When compared to remdesivir (-6.38), cyclocurcumin from turmeric is significantly more active. The docking results of the compounds exhibited similar mode of interactions with SARS CoV-2. Main protease and the residues THR24, THR25, THR26, LEU27, SER46, MET49, HIE41, GLN189, ARG188, ASP187, MET165, HIE164, PHE181, and THR54 play a crucial role in binding with ligands. Conclusion: Based on in silico investigations, the chemical constituents from turmeric like cyclocurcumin and curcumin and from Andrographis paniculata like andrographolide and dihydroxy dimethoxy flavone, significantly binding with the active site of SARS CoV-2 main protease, may produce significant activity and be useful for further development.
Abbreviations COVID-19: Coronavirus disease 2019; MM-GBSA: Molecular mechanicsgeneralized Born surface area; PDB: Protein data bank; OPLS3: Optimized potentials for liquid simulations; XP: Extra precision Authors' contributions The authors KR and GB contributed to the technical and preparation of the manuscript. PV and BA contributed to the collection of literature and preparation of the manuscript. All authors have read and approved the manuscript and ensure that this is the case. Ethics approval and consent to participate Not applicable Consent for publication Not applicable Competing interests The authors have no competing interests to declare. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Abe, Hashimoto, Horie, Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages, Pharmacol Res
Aggarwal, Kumar, Bharti, Anticancer potential of curcumin: preclinical and clinical studies, Anticancer Res
Akbar, Andrographis paniculata: a review of pharmacological activities and clinical effects, Altern Med Rev
Bhatia, Singh, Khanna, Effect of curcumin, its alkali salts and Curcuma longa oil in histamine-induced gastric ulceration, Indian J Exp Biol
Boopathi, Andrographis spp.: a source of bitter compounds for medicinal use, Anc Sci Life
Borhanuddin, Shamsuzzoha, Hussain, Hypoglycaemic effects of Andrographis paniculata Nees on nondiabetic rabbits, Bangladesh Med Res Counc Bull
Calisher, Carroll, Colwell, Corley, Daszak et al., Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19, Lancet
Chang, Yan, Wang, Coronavirus disease 2019: coronaviruses and blood safety, Transfus Med Rev, doi:10.1016/j.tmrv.2020.02.003
Chaturvedi, Tomar, Tiwari, Singh, Clinical studies on Kalmegh (Andrographis paniculata Nees) in infective hepatitis, J Int Inst Ayurveda
Cross, Chloroquine's use to treat COVID-19 is backed by US government, but many questions remain, Drug Dev
Dua, Ojha, Roy, Joshi, Valecha et al., Antimalarial activity of some xanthones isolated from the roots of Andrographis paniculata, J Ethnopharmacol
Friesner, Murphy, Repasky, Frye, Greenwood et al., Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, J Med Chem
Gu, Han, Wang, COVID-19: gastrointestinal manifestations and potential fecal-oral transmission, Gastroenterology, doi:10.1053/j.gastro.2020.02.054
Gupta, Ghosh, Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells, Int J Immunopharmacol
Haddad, Sauvain, Deharo, Curcuma as a parasiticidal agent: a review, Planta Med, doi:10.1055/s-0030-1250549
Holshue, Debolt, Lindquist, Lindquist, Lofy et al., First case of 2019 novel coronavirus in the United States, N Engl J Med, doi:10.1056/NEJMoa2001191
Huang, Herrmann, Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV), Bio Rxiv, doi:10.1101/2020.02.01.930537
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, doi:10.1016/s0140-6736(20)30183-5
Husen, Pihie, Nallappan, Screening for antihyperglycaemic activity in several local herbs of Malaysia, J Ethnopharmacol
Jacobson, Pincus, Rapp, Day, Honig et al., A hierarchical approach to all-atom protein loop prediction, Proteins
Jade, Suburb, Matthews, Hamzah, Lapis et al., Semisynthesis and in vitro anticancer activities of andrographolide analogues, Phytochem
Jarukamjorn, Nemoto, Pharmacological aspects of Andrographis paniculata on health and its major diterpenoid constituent andrographolide, J Health Sci
Kabir, Hasan, Rahman, Khan, Hoque et al., A survey of medicinal plants used by the Deb barma clan of the Tripura tribe of Moulvibazar district, Bangladesh, J Ethnobiol Ethnomed
Kalirajan, Gaurav, Pandiselvi, Gowramma, Sankar, Novel thiazine substituted 9-anilinoacridines: synthesis, antitumour activity and structure-activity relationships, Anti-Cancer Agents Med Chem, doi:10.2174/1871520619666190408134224
Kalirajan, Gowramma, Jubie, Sankar, Molecular docking studies and in silico ADMET screening of some novel heterocyclic substituted 9anilinoacridines as topoisomerase II inhibitors, JSM Chem
Kalirajan, Mohammed Rafick, Jubie, Sankar, Docking studies, synthesis, characterization and evaluation of their antioxidant and cytotoxic activities of some novel isoxazole substituted 9-anilinoacridine derivatives, Sci World J, doi:10.1100/2012/165258
Kalirajan, Mohammed Rafick, Sankar, Gowramma, Green synthesis of some novel chalcone and isoxazole substituted 9anilinoacridine derivatives and evaluation of their antimicrobial and larvicidal activities, Indian J Chem
Kalirajan, Muralidharan, Jubie, Gowramma, Gomathy et al., Synthesis of some novel pyrazole substituted 9anilinoacridine derivatives and evaluation for their antioxidant and cytotoxic activities, J Heterocyclic Chem
Kalirajan, Muralidharan, Jubie, Sankar, Microwave assisted synthesis, characterization and evaluation for their antimicrobial activities of some novel pyrazole substituted 9-anilino acridine derivatives, Int J Health Allied Sci
Kalirajan, Pandiselvi, Gowramma, Balachandran, In-silico design, ADMET screening, MM-GBSA binding free energy of some novel isoxazole substituted9-anilinoacridines as HER2 inhibitors targeting breast cancer, Curr Drug Res Rev
Kalirajan, Rathore, Jubie, Gowramma, Gomathy et al., Microwave assisted synthesis of some novel pyrazole substituted benzimidazoles and evaluation of their biological activities, Indian J Chem
Kalirajan, Sankar, Jubie, Docking studies, synthesis, characterization of some novel oxazine substituted 9-anilinoacridine derivatives and evaluation for their anti-oxidant and anticancer activities as topo isomerase II inhibitors, Eur J Med Chem
Kalirajan, Sankar, Jubie, Gowramma, Molecular docking studies and in-silico ADMET screening of some novel oxazine substituted 9-anilinoacridines as topoisomerase II inhibitors, Indian J Pharm Educ Res
Kalirajan, Vivek, Sankar, Synthesis, characterization and evaluation for antitumour activity of some novel oxazine substituted 9anilinoacridines and their 3D-QSAR studies, Indian J Pharm Sci
Kim, Park, Kim, Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult, Neurosci Lett
Kuroda, Mimaki, Nishiyama, Kishida, Tsukagawa, Hypoglycemic effects of turmeric (Curcuma longa L. Rhizomes) on genetically diabetic KK-A y mice, Biol Pharm Bull
Li, Abel, Zhu, Cao, Zhao et al., The VSGB 2.0 model: a next generation energy model for high resolution protein structure modelling, Proteins
Lu, Zhao, Li, Niu, Yang et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, doi:10.1016/S0140-6736(20)30251-8
Parichatikanond, Suthisisang, Dhepakson, Herunsalee, Study of anti-inflammatory activities of the pure compounds from Andrographis paniculata (Burm.f.) Nees and their effects on gene expression, Int Immunopharmacol
Parthasarathy, Chempakam, Zachariah, Chemistry of spices. United Kingdom
Prakash, Misra, Surin, Jain, Bhatta et al., Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemiareperfusion and thrombosis, Thromb Res, doi:10.1016/j.thromres.2010.11.007
Ramirez-Tortosa, Mesa, Aguilera, Quiles, Baro et al., Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis, Atherosclerosis
Sastry, Adzhigirey, Day, Annabhimoju, Sherman, Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments, J Comp Aided Mol Design
Srivastava, Dikshit, Srimal, Dhawan, Anti-thrombotic effect of curcumin, Thromb Res
To, Tsang, Yip, Chan, Wu et al., Consistent detection of 2019 novel coronavirus in saliva, Clin Infect Dis, doi:10.1093/cid/ciaa149
Wang, Hu, Hu, Xiong, Zhao et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Zhang, Kang, Gong, Xu, Wang et al., The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes, bioRxiv, doi:10.1101/2020.01.30.927806
Zhou, Hou, Shen, Huang, Martin et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discov
Zhou, Yang, Wang, Hu, Zhang et al., A pneumonia associated with a new coronavirus of probable bat origin, Nature, doi:10.1038/s41586-020-2012-7
DOI record: { "DOI": "10.1186/s43094-020-00126-x", "ISSN": [ "2314-7253" ], "URL": "http://dx.doi.org/10.1186/s43094-020-00126-x", "abstract": "<jats:title>Abstract</jats:title><jats:sec>\n<jats:title>Background</jats:title>\n<jats:p>In early 2020, many scientists are rushing to discover novel drugs and vaccines against the coronavirus, and treatments for COVID-19, because coronavirus disease 2019 (COVID-19), a life-threatening viral disease, affected first in China and quickly spread throughout the world. In this article, in silico studies have been performed to explore the binding modes of chemical constituents for natural remedies like <jats:italic>Curcuma longa</jats:italic> (turmeric) and <jats:italic>Andrographis paniculata</jats:italic> against COVID-19 (PDB ID 5R82) targeting coronavirus using Schrodinger suit 2019-4. The molecular docking studies are performed by the Glide module, in silico ADMET screening was performed by the QikProp module, and binding energy of ligands was calculated using the Prime MM-GB/SA module.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Results</jats:title>\n<jats:p>The chemical constituents from turmeric like cyclocurcumin and curcumin and from <jats:italic>Andrographis paniculata</jats:italic> like andrographolide and dihydroxy dimethoxy flavone are significantly binding with the active site of SARS CoV-2 main protease with Glide score more than − 6 when compared to the currently used drugs hydroxychloroquine (− 5.47) and nelfinavir (− 5.93). When compared to remdesivir (− 6.38), cyclocurcumin from turmeric is significantly more active. The docking results of the compounds exhibited similar mode of interactions with SARS CoV-2. Main protease and the residues THR24, THR25, THR26, LEU27, SER46, MET49, HIE41, GLN189, ARG188, ASP187, MET165, HIE164, PHE181, and THR54 play a crucial role in binding with ligands.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Conclusion</jats:title>\n<jats:p>Based on in silico investigations, the chemical constituents from turmeric like cyclocurcumin and curcumin and from <jats:italic>Andrographis paniculata</jats:italic> like andrographolide and dihydroxy dimethoxy flavone, significantly binding with the active site of SARS CoV-2 main protease, may produce significant activity and be useful for further development.</jats:p>\n</jats:sec>", "alternative-id": [ "126" ], "article-number": "104", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "23 April 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "4 October 2020" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "16 October 2020" }, { "group": { "label": "Ethics approval and consent to participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "Not applicable" }, { "group": { "label": "Consent for publication", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "Not applicable" }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "The authors have no competing interests to declare." } ], "author": [ { "ORCID": "http://orcid.org/0000-0003-3382-4316", "affiliation": [], "authenticated-orcid": false, "family": "Rajagopal", "given": "Kalirajan", "sequence": "first" }, { "affiliation": [], "family": "Varakumar", "given": "Potlapati", "sequence": "additional" }, { "affiliation": [], "family": "Baliwada", "given": "Aparma", "sequence": "additional" }, { "affiliation": [], "family": "Byran", "given": "Gowramma", "sequence": "additional" } ], "container-title": "Future Journal of Pharmaceutical Sciences", "container-title-short": "Futur J Pharm Sci", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2020, 10, 16 ] ], "date-time": "2020-10-16T10:03:38Z", "timestamp": 1602842618000 }, "deposited": { "date-parts": [ [ 2021, 10, 16 ] ], "date-time": "2021-10-16T06:56:48Z", "timestamp": 1634367408000 }, "indexed": { "date-parts": [ [ 2023, 11, 25 ] ], "date-time": "2023-11-25T05:59:22Z", "timestamp": 1700891962425 }, "is-referenced-by-count": 57, "issue": "1", "issued": { "date-parts": [ [ 2020, 10, 16 ] ] }, "journal-issue": { "issue": "1", "published-print": { "date-parts": [ [ 2020, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 16 ] ], "date-time": "2020-10-16T00:00:00Z", "timestamp": 1602806400000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 16 ] ], "date-time": "2020-10-16T00:00:00Z", "timestamp": 1602806400000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1186/s43094-020-00126-x.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1186/s43094-020-00126-x/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1186/s43094-020-00126-x.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1186", "published": { "date-parts": [ [ 2020, 10, 16 ] ] }, "published-online": { "date-parts": [ [ 2020, 10, 16 ] ] }, "published-print": { "date-parts": [ [ 2020, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1001/jama.2020.1585", "author": "D Wang", "doi-asserted-by": "publisher", "first-page": "1061", "issue": "11", "journal-title": "JAMA.", "key": "126_CR1", "unstructured": "Wang D, Hu B, Hu C, Xiong, Zhao, Li, Wang X, Peng (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 323(11):1061–1069. https://doi.org/10.1001/jama.2020.1585", "volume": "323", "year": "2020" }, { "DOI": "10.1056/NEJMoa2001191", "doi-asserted-by": "publisher", "key": "126_CR2", "unstructured": "Holshue ML, DeBolt C, Lindquist S, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Sara Wilkerson MN, Tural A, Diaz G, Cohn A, Fox LA, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med. https://doi.org/10.1056/NEJMoa2001191" }, { "DOI": "10.1038/s41421-020-0153-3", "author": "Y Zhou", "doi-asserted-by": "publisher", "first-page": "14", "journal-title": "Cell Discov", "key": "126_CR3", "unstructured": "Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F (2020) Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 6:14–18", "volume": "6", "year": "2020" }, { "DOI": "10.1053/j.gastro.2020.02.054", "doi-asserted-by": "publisher", "key": "126_CR4", "unstructured": "Gu J, Han B, Wang J (2020) COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. https://doi.org/10.1053/j.gastro.2020.02.054" }, { "DOI": "10.1016/S0140-6736(20)30418-9", "author": "C Calisher", "doi-asserted-by": "publisher", "first-page": "e42", "issue": "10226", "journal-title": "Lancet.", "key": "126_CR5", "unstructured": "Calisher C, Carroll D, Colwell R, Corley RB, Daszak P, Drosten C, Enjuanes L, Farrar J, Field H, Golding J (2020) Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. Lancet. 395(10226):e42–e43", "volume": "395", "year": "2020" }, { "DOI": "10.1093/cid/ciaa149", "author": "KK-W To", "doi-asserted-by": "publisher", "first-page": "841", "issue": "15", "journal-title": "Clin Infect Dis", "key": "126_CR6", "unstructured": "To KK-W, Tsang OT-Y, Yip CC-Y, Chan K-H, Wu T-C, Chan JM-C, Leung W-S, Chik TS-H, Choi CY-C, Kandamby DH (2020) Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 71(15):841–843. https://doi.org/10.1093/cid/ciaa149", "volume": "71", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30251-8", "doi-asserted-by": "publisher", "key": "126_CR7", "unstructured": "Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Liang W, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Yang L, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. https://doi.org/10.1016/S0140-6736(20)30251-8" }, { "DOI": "10.1038/s41586-020-2012-7", "author": "P Zhou", "doi-asserted-by": "publisher", "first-page": "270", "journal-title": "Nature.", "key": "126_CR8", "unstructured": "Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579:270–273. https://doi.org/10.1038/s41586-020-2012-7", "volume": "579", "year": "2020" }, { "DOI": "10.1101/2020.02.01.930537", "doi-asserted-by": "publisher", "key": "126_CR9", "unstructured": "Huang Q, Herrmann A (2020) Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV). Bio Rxiv. https://doi.org/10.1101/2020.02.01.930537" }, { "DOI": "10.1101/2020.01.30.927806", "doi-asserted-by": "publisher", "key": "126_CR10", "unstructured": "Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, Cui X, Xiao J, Meng T, Wang Z, Liu J, Xu H (2020) The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv:927806. https://doi.org/10.1101/2020.01.30.927806" }, { "DOI": "10.1016/j.tmrv.2020.02.003", "doi-asserted-by": "publisher", "key": "126_CR11", "unstructured": "Chang, L., Yan,Y., Wang, L. (2020) Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. https://doi.org/10.1016/j.tmrv.2020.02.003." }, { "DOI": "10.1016/s0140-6736(20)30183-5", "doi-asserted-by": "publisher", "key": "126_CR12", "unstructured": "Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. https://doi.org/10.1016/s0140-6736(20)30183-5." }, { "DOI": "10.1016/j.thromres.2010.11.007", "author": "P Prakash", "doi-asserted-by": "publisher", "first-page": "111", "journal-title": "Thromb Res", "key": "126_CR13", "unstructured": "Prakash P, Misra A, Surin WR, Jain M, Bhatta RS, Pal R (2011) Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. Thromb Res 127:111–118. https://doi.org/10.1016/j.thromres.2010.11.007", "volume": "127", "year": "2011" }, { "DOI": "10.1248/bpb.28.937", "author": "M Kuroda", "doi-asserted-by": "publisher", "first-page": "937", "journal-title": "Biol Pharm Bull", "key": "126_CR14", "unstructured": "Kuroda M, Mimaki Y, Nishiyama T, Mae T, Kishida H, Tsukagawa K (2005) Hypoglycemic effects of turmeric (Curcuma longa L. Rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull 5:937–939", "volume": "5", "year": "2005" }, { "author": "BB Aggarwal", "first-page": "363", "issue": "1A", "journal-title": "Anticancer Res", "key": "126_CR15", "unstructured": "Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23(1A):363–398", "volume": "23", "year": "2003" }, { "DOI": "10.1079/9781845934057.0000", "doi-asserted-by": "crossref", "key": "126_CR16", "unstructured": "Parthasarathy VA, Chempakam B, Zachariah TJ (2008) Chemistry of spices. United Kingdom. CABI:445–447" }, { "DOI": "10.1055/s-0030-1250549", "author": "M Haddad", "doi-asserted-by": "publisher", "first-page": "672", "journal-title": "Planta Med", "key": "126_CR17", "unstructured": "Haddad M, Sauvain M, Deharo E (2010) Curcuma as a parasiticidal agent: a review. Planta Med 77:672–678. https://doi.org/10.1055/s-0030-1250549", "volume": "77", "year": "2010" }, { "DOI": "10.1006/phrs.1998.0404", "author": "Y Abe", "doi-asserted-by": "publisher", "first-page": "41", "issue": "1", "journal-title": "Pharmacol Res", "key": "126_CR18", "unstructured": "Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39(1):41–47", "volume": "39", "year": "1999" }, { "DOI": "10.1016/S0192-0561(99)00050-8", "author": "B Gupta", "doi-asserted-by": "publisher", "first-page": "745", "issue": "11", "journal-title": "Int J Immunopharmacol", "key": "126_CR19", "unstructured": "Gupta B, Ghosh B (1999) Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int J Immunopharmacol 21(11):745–757", "volume": "21", "year": "1999" }, { "DOI": "10.1016/0049-3848(85)90276-2", "author": "R Srivastava", "doi-asserted-by": "publisher", "first-page": "413", "issue": "3", "journal-title": "Thromb Res", "key": "126_CR20", "unstructured": "Srivastava R, Dikshit M, Srimal RC, Dhawan BN (1985) Anti-thrombotic effect of curcumin. Thromb Res 40(3):413–417", "volume": "40", "year": "1985" }, { "author": "A Bhatia", "first-page": "158", "journal-title": "Indian J Exp Biol", "key": "126_CR21", "unstructured": "Bhatia A, Singh GB, Khanna NM (1964) Effect of curcumin, its alkali salts and Curcuma longa oil in histamine-induced gastric ulceration. Indian J Exp Biol 2:158–160", "volume": "2", "year": "1964" }, { "DOI": "10.1016/S0021-9150(99)00207-5", "author": "MC Ramirez-Tortosa", "doi-asserted-by": "publisher", "first-page": "371", "issue": "2", "journal-title": "Atherosclerosis", "key": "126_CR22", "unstructured": "Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L, Ramirez-Tortosa CL, Martinez-Victoria E, Gil A (1999) Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 147(2):371–378", "volume": "147", "year": "1999" }, { "DOI": "10.1016/S0304-3940(01)01677-9", "author": "DS Kim", "doi-asserted-by": "publisher", "first-page": "57", "issue": "1", "journal-title": "Neurosci Lett", "key": "126_CR23", "unstructured": "Kim DS, Park SY, Kim JK (2001) Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci Lett 303(1):57–61", "volume": "303", "year": "2001" }, { "author": "C Boopathi", "first-page": "164", "issue": "3-4", "journal-title": "Anc Sci Life", "key": "126_CR24", "unstructured": "Boopathi C (2000) Andrographis spp.: a source of bitter compounds for medicinal use. Anc Sci Life 19(3-4):164–168", "volume": "19", "year": "2000" }, { "DOI": "10.1248/jhs.54.370", "author": "K Jarukamjorn", "doi-asserted-by": "publisher", "first-page": "370", "issue": "4", "journal-title": "J Health Sci", "key": "126_CR25", "unstructured": "Jarukamjorn K, Nemoto N (2008) Pharmacological aspects of Andrographis paniculata on health and its major diterpenoid constituent andrographolide. J Health Sci 54(4):370–381", "volume": "54", "year": "2008" }, { "DOI": "10.1186/1746-4269-10-19", "author": "MH Kabir", "doi-asserted-by": "publisher", "first-page": "19", "issue": "1", "journal-title": "J Ethnobiol Ethnomed", "key": "126_CR26", "unstructured": "Kabir MH, Hasan N, Rahman MM, Khan JA, Hoque NT, Quddus Bhuiyan MR, Mou SM, Jahan R, Rahmatullah M (2014) A survey of medicinal plants used by the Deb barma clan of the Tripura tribe of Moulvibazar district, Bangladesh. J Ethnobiol Ethnomed 10(1):19", "volume": "10", "year": "2014" }, { "author": "M Borhanuddin", "first-page": "24", "issue": "1", "journal-title": "Bangladesh Med Res Counc Bull", "key": "126_CR27", "unstructured": "Borhanuddin M, Shamsuzzoha M, Hussain AH (1994) Hypoglycaemic effects of Andrographis paniculata Nees on nondiabetic rabbits. Bangladesh Med Res Counc Bull 20(1):24–26", "volume": "20", "year": "1994" }, { "author": "S Akbar", "first-page": "66", "issue": "1", "journal-title": "Altern Med Rev", "key": "126_CR28", "unstructured": "Akbar S (2011) Andrographis paniculata: a review of pharmacological activities and clinical effects. Altern Med Rev 16(1):66–77", "volume": "16", "year": "2011" }, { "author": "GN Chaturvedi", "first-page": "208", "journal-title": "J Int Inst Ayurveda", "key": "126_CR29", "unstructured": "Chaturvedi GN, Tomar GS, Tiwari SK, Singh KP (1983) Clinical studies on Kalmegh (Andrographis paniculata Nees) in infective hepatitis. J Int Inst Ayurveda 2:208–211", "volume": "2", "year": "1983" }, { "DOI": "10.1016/j.jep.2004.07.008", "author": "VK Dua", "doi-asserted-by": "publisher", "first-page": "247", "journal-title": "J Ethnopharmacol", "key": "126_CR30", "unstructured": "Dua VK, Ojha VP, Roy R, Joshi BC, Valecha N, Devi CU et al (2004) Anti-malarial activity of some xanthones isolated from the roots of Andrographis paniculata. J Ethnopharmacol 95:247–251", "volume": "95", "year": "2004" }, { "DOI": "10.1016/j.intimp.2010.08.002", "author": "W Parichatikanond", "doi-asserted-by": "publisher", "first-page": "1361", "journal-title": "Int Immunopharmacol", "key": "126_CR31", "unstructured": "Parichatikanond W, Suthisisang C, Dhepakson P, Herunsalee A (2010) Study of anti-inflammatory activities of the pure compounds from Andrographis paniculata (Burm.f.) Nees and their effects on gene expression. Int Immunopharmacol 10:1361–1373", "volume": "10", "year": "2010" }, { "DOI": "10.1016/j.phytochem.2006.11.031", "author": "SR Jade", "doi-asserted-by": "publisher", "first-page": "904", "journal-title": "Phytochem", "key": "126_CR32", "unstructured": "Jade SR, Suburb GS, Matthews C, Hamzah AS, Lapis NH, Saad MS (2007) Semisynthesis and in vitro anticancer activities of andrographolide analogues. Phytochem 68:904–912", "volume": "68", "year": "2007" }, { "DOI": "10.1016/j.jep.2004.07.004", "author": "R Husen", "doi-asserted-by": "publisher", "first-page": "205", "journal-title": "J Ethnopharmacol", "key": "126_CR33", "unstructured": "Husen R, Pihie AH, Nallappan M (2004) Screening for antihyperglycaemic activity in several local herbs of Malaysia. J Ethnopharmacol 95:205–208", "volume": "95", "year": "2004" }, { "author": "R Kalirajan", "first-page": "583", "journal-title": "Indian J Chem", "key": "126_CR34", "unstructured": "Kalirajan R, Mohammed rafick MH, Sankar S, Gowramma B (2018) Green synthesis of some novel chalcone and isoxazole substituted 9-anilinoacridine derivatives and evaluation of their antimicrobial and larvicidal activities. Indian J Chem 57B:583–590", "volume": "57B", "year": "2018" }, { "DOI": "10.4103/2278-344X.115682", "author": "R Kalirajan", "doi-asserted-by": "publisher", "first-page": "81", "issue": "2", "journal-title": "Int J Health Allied Sci", "key": "126_CR35", "unstructured": "Kalirajan R, Muralidharan V, Jubie S, Sankar S (2013) Microwave assisted synthesis, characterization and evaluation for their antimicrobial activities of some novel pyrazole substituted 9-anilino acridine derivatives. Int J Health Allied Sci 2(2):81–87", "volume": "2", "year": "2013" }, { "DOI": "10.1002/jhet.848", "author": "R Kalirajan", "doi-asserted-by": "publisher", "first-page": "748", "journal-title": "J Heterocyclic Chem", "key": "126_CR36", "unstructured": "Kalirajan R, Muralidharan V, Jubie S, Gowramma B, Gomathy S, Sankar S, Elango K (2012) Synthesis of some novel pyrazole substituted 9-anilinoacridine derivatives and evaluation for their antioxidant and cytotoxic activities. J Heterocyclic Chem 49:748–754", "volume": "49", "year": "2012" }, { "DOI": "10.1100/2012/165258", "doi-asserted-by": "publisher", "key": "126_CR37", "unstructured": "Kalirajan R, Mohammed rafick MH, Jubie S, Sankar S (2012) Docking studies, synthesis, characterization and evaluation of their antioxidant and cytotoxic activities of some novel isoxazole substituted 9-anilinoacridine derivatives. Sci World J:165258. https://doi.org/10.1100/2012/165258" }, { "DOI": "10.1016/j.ejmech.2012.08.025", "author": "R Kalirajan", "doi-asserted-by": "publisher", "first-page": "217", "journal-title": "Eur J Med Chem", "key": "126_CR38", "unstructured": "Kalirajan R, kulshrestha V, Sankar S, Jubie S (2012) Docking studies, synthesis, characterization of some novel oxazine substituted 9-anilinoacridine derivatives and evaluation for their anti-oxidant and anticancer activities as topo isomerase II inhibitors. Eur J Med Chem 56:217–224", "volume": "56", "year": "2012" }, { "author": "R Kalirajan", "first-page": "1794", "journal-title": "Indian J Chem", "key": "126_CR39", "unstructured": "Kalirajan R, Rathore L, Jubie S, Gowramma B, Gomathy S, Sankar S (2011) Microwave assisted synthesis of some novel pyrazole substituted benzimidazoles and evaluation of their biological activities. Indian J Chem 50B:1794–1801", "volume": "50B", "year": "2011" }, { "DOI": "10.5530/ijper.51.1.15", "author": "R Kalirajan", "doi-asserted-by": "publisher", "first-page": "110", "issue": "1", "journal-title": "Indian J Pharm Educ Res", "key": "126_CR40", "unstructured": "Kalirajan R, Sankar S, Jubie S, Gowramma B (2017) Molecular docking studies and in-silico ADMET screening of some novel oxazine substituted 9-anilinoacridines as topoisomerase II inhibitors. Indian J Pharm Educ Res 51(1):110–115", "volume": "51", "year": "2017" }, { "author": "R Kalirajan", "first-page": "1039", "issue": "1", "journal-title": "JSM Chem", "key": "126_CR41", "unstructured": "Kalirajan R, Gowramma B, Jubie S, Sankar S (2017) Molecular docking studies and in silico ADMET screening of some novel heterocyclic substituted 9-anilinoacridines as topoisomerase II inhibitors. JSM Chem 5(1):1039–1044", "volume": "5", "year": "2017" }, { "DOI": "10.2174/1871520619666190408134224", "author": "R Kalirajan", "doi-asserted-by": "publisher", "first-page": "1350", "journal-title": "Anti-Cancer Agents Med Chem", "key": "126_CR42", "unstructured": "Kalirajan R, Gaurav K, Pandiselvi A, Gowramma B, Sankar S (2019) Novel thiazine substituted 9-anilinoacridines: synthesis, antitumour activity and structure-activity relationships. Anti-Cancer Agents Med Chem 11:1350–1358. https://doi.org/10.2174/1871520619666190408134224", "volume": "11", "year": "2019" }, { "DOI": "10.4172/pharmaceutical-sciences.1000439", "author": "R Kalirajan", "doi-asserted-by": "publisher", "first-page": "921", "issue": "5", "journal-title": "Indian J Pharm Sci", "key": "126_CR43", "unstructured": "Kalirajan R, Vivek kulshrestha, Sankar, S. (2018) Synthesis, characterization and evaluation for antitumour activity of some novel oxazine substituted 9-anilinoacridines and their 3D-QSAR studies. Indian J Pharm Sci 80(5):921–929", "volume": "80", "year": "2018" }, { "DOI": "10.2174/2589977511666190912154817", "author": "R Kalirajan", "doi-asserted-by": "publisher", "first-page": "118", "issue": "2", "journal-title": "Curr Drug Res Rev", "key": "126_CR44", "unstructured": "Kalirajan R, Pandiselvi A, Gowramma B, Balachandran P (2019) In-silico design, ADMET screening, MM-GBSA binding free energy of some novel isoxazole substituted9-anilinoacridines as HER2 inhibitors targeting breast cancer. Curr Drug Res Rev 11(2):118–128", "volume": "11", "year": "2019" }, { "DOI": "10.1007/s10822-013-9644-8", "author": "GM Sastry", "doi-asserted-by": "publisher", "first-page": "221", "journal-title": "J Comp Aided Mol Design", "key": "126_CR45", "unstructured": "Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comp Aided Mol Design 27:221–234", "volume": "27", "year": "2013" }, { "DOI": "10.1002/prot.10613", "author": "MP Jacobson", "doi-asserted-by": "publisher", "first-page": "351", "journal-title": "Proteins", "key": "126_CR46", "unstructured": "Jacobson MP, Pincus DL, Rapp CS, Day TJF, Honig B, Shaw DE, Friesner RA (2004) A hierarchical approach to all-atom protein loop prediction. Proteins 55:351–367", "volume": "55", "year": "2004" }, { "DOI": "10.1021/jm051256o", "author": "RA Friesner", "doi-asserted-by": "publisher", "first-page": "6177", "journal-title": "J Med Chem", "key": "126_CR47", "unstructured": "Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. J Med Chem 49:6177–6196", "volume": "49", "year": "2006" }, { "DOI": "10.1002/prot.23106", "author": "J Li", "doi-asserted-by": "publisher", "first-page": "2794", "journal-title": "Proteins", "key": "126_CR48", "unstructured": "Li J, Abel R, Zhu K, Cao Y, Zhao S, Friesner RA (2011) The VSGB 2.0 model: a next generation energy model for high resolution protein structure modelling. Proteins 79:2794–2812", "volume": "79", "year": "2011" }, { "key": "126_CR49", "unstructured": "Cross R (2020) Chloroquine’s use to treat COVID-19 is backed by US government, but many questions remain. Drug Dev 98(12)" } ], "reference-count": 49, "references-count": 49, "relation": {}, "resource": { "primary": { "URL": "https://fjps.springeropen.com/articles/10.1186/s43094-020-00126-x" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "General Medicine" ], "subtitle": [], "title": "Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "6" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit